170 related articles for article (PubMed ID: 38296248)
1. Mno
Duan J; Zhao S; Duan Y; Sun D; Zhang G; Yu D; Lou Y; Liu H; Yang S; Liang X; Ma C; Liu H; Qiu J; Gao L; Sang Y
Adv Healthc Mater; 2024 Apr; 13(11):e2303963. PubMed ID: 38296248
[TBL] [Abstract][Full Text] [Related]
2. Purinergic targeting enhances immunotherapy of CD73
Wang J; Lupo KB; Chambers AM; Matosevic S
J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
[TBL] [Abstract][Full Text] [Related]
3. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
[TBL] [Abstract][Full Text] [Related]
4. Reversing Hypoxia with PLGA-Encapsulated Manganese Dioxide Nanoparticles Improves Natural Killer Cell Response to Tumor Spheroids.
Murphy DA; Cheng H; Yang T; Yan X; Adjei IM
Mol Pharm; 2021 Aug; 18(8):2935-2946. PubMed ID: 34191525
[TBL] [Abstract][Full Text] [Related]
5. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.
Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment.
Grote S; Ureña-Bailén G; Chan KC; Baden C; Mezger M; Handgretinger R; Schleicher S
Cells; 2021 Apr; 10(5):. PubMed ID: 33925968
[TBL] [Abstract][Full Text] [Related]
7. Synergistic treatment strategy: combining CAR-NK cell therapy and radiotherapy to combat solid tumors.
He J; Yan Y; Zhang J; Wei Z; Li H; Xing L
Front Immunol; 2023; 14():1298683. PubMed ID: 38162672
[TBL] [Abstract][Full Text] [Related]
8. Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment.
Portillo AL; Monteiro JK; Rojas EA; Ritchie TM; Gillgrass A; Ashkar AA
Front Immunol; 2023; 14():1286750. PubMed ID: 38022679
[TBL] [Abstract][Full Text] [Related]
9. Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy.
Zhao Y; Zhou X
Immunotherapy; 2020 Jun; 12(9):653-664. PubMed ID: 32436428
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in CAR-Based Solid Tumor Immunotherapy.
Shin MH; Oh E; Kim Y; Nam DH; Jeon SY; Yu JH; Minn D
Cells; 2023 Jun; 12(12):. PubMed ID: 37371075
[TBL] [Abstract][Full Text] [Related]
11. Tumor homing-penetrating and nanoenzyme-augmented 2D phototheranostics against hypoxic solid tumors.
Wu C; Zhang Y; Wei X; Li N; Huang H; Xie Z; Zhang H; Yang G; Li M; Li T; Yang H; Li S; Qin X; Liu Y
Acta Biomater; 2022 Sep; 150():391-401. PubMed ID: 35917909
[TBL] [Abstract][Full Text] [Related]
12. Nanoenzyme-Augmented Cancer Sonodynamic Therapy by Catalytic Tumor Oxygenation.
Zhu P; Chen Y; Shi J
ACS Nano; 2018 Apr; 12(4):3780-3795. PubMed ID: 29613770
[TBL] [Abstract][Full Text] [Related]
13. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
14. ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
Merker M; Wagner J; Kreyenberg H; Heim C; Moser LM; Wels WS; Bonig H; Ivics Z; Ullrich E; Klingebiel T; Bader P; Rettinger E
Front Immunol; 2020; 11():581468. PubMed ID: 33193388
[TBL] [Abstract][Full Text] [Related]
15. Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors.
Ghaedrahmati F; Esmaeil N; Abbaspour M
Cancer Commun (Lond); 2023 Feb; 43(2):177-213. PubMed ID: 36585761
[TBL] [Abstract][Full Text] [Related]
16. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
[TBL] [Abstract][Full Text] [Related]
17. CAR-NK cell in cancer immunotherapy; A promising frontier.
Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M
Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690
[TBL] [Abstract][Full Text] [Related]
18. Overcoming chemotherapy resistance using pH-sensitive hollow MnO
Zhou ZH; Liang SY; Zhao TC; Chen XZ; Cao XK; Qi M; Huang YY; Ju WT; Yang M; Zhu DW; Pang YC; Zhong LP
J Nanobiotechnology; 2021 May; 19(1):157. PubMed ID: 34039370
[TBL] [Abstract][Full Text] [Related]
19. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
[TBL] [Abstract][Full Text] [Related]
20. Artesunate-loaded poly (lactic-co-glycolic acid)/polydopamine-manganese oxides nanoparticles as an oxidase mimic for tumor chemo-catalytic therapy.
Xi J; Huang Y; Chen J; Zhang J; Gao L; Fan L; Qian X
Int J Biol Macromol; 2021 Jun; 181():72-81. PubMed ID: 33771546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
